PMID- 35995416
OWN - NLM
STAT- MEDLINE
DCOM- 20221006
LR  - 20221011
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Print)
IS  - 1341-321X (Linking)
VI  - 28
IP  - 12
DP  - 2022 Dec
TI  - Factors related to the serious adverse events in patients visiting the emergency 
      department after ChAdOx1 and mRNA COVID-19 vaccination.
PG  - 1616-1622
LID - S1341-321X(22)00239-2 [pii]
LID - 10.1016/j.jiac.2022.08.013 [doi]
AB  - INTRODUCTION: We investigated the clinical characteristics, outcomes and factors 
      related to the serious adverse events (AEs) of patients visiting the emergency 
      department (ED) with various AEs after ChAdOx1 and mRNA COVID-19 vaccination. 
      METHODS: Patients with AEs who visited the ED between March 2021 and September 
      2021 were selected from three EDs. The clinical data of these patients were 
      collected by retrospectively reviewing medical records. Serious adverse events 
      (AEs) were defined as any adverse medical events that led to hospital admission. 
      RESULTS: A total of 3572 patients visited the ED with AEs; 69.6% were 
      administered mRNA vaccines, and the median (IQR) age was 48 (31-63) years. 
      Regarding chief complaints, chest pain/discomfort (43.7%) was most common in the 
      mRNA vaccines group, while fever (15.8%) was more commonly presented in the 
      ChAdOx1 group. Most patients (93.9%) were discharged from the ED. In multivariate 
      analysis, age >/=70 years, days from vaccination to ED visit >/=8 days, fever and 
      dyspnea as chief complaints were higher independent risk factors for serious AEs 
      (OR 27.94, OR 2.55, OR 1.95 and OR 2.18: p < 0.001, p < 0.001, p = 0.003 and 
      p = 0.003, respectively). CONCLUSION: Most patients who visited the ED with AEs 
      after vaccination were discharged from the ED regardless of the type of vaccine. 
      Emergency physicians need to differentiate serious AEs and consider factors that 
      may require admission to the ED.
CI  - Copyright (c) 2022 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Jeong, Won Jung
AU  - Jeong WJ
AD  - Department of Emergency Medicine, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, South Korea.
FAU - So, Byung Hak
AU  - So BH
AD  - Department of Emergency Medicine, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, South Korea.
FAU - Kim, Hyung Min
AU  - Kim HM
AD  - Department of Emergency Medicine, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, South Korea.
FAU - Cha, Kyungman
AU  - Cha K
AD  - Department of Emergency Medicine, St. Vincent's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, South Korea.
FAU - Lee, Woon Jeong
AU  - Lee WJ
AD  - Department of Emergency Medicine, Incheon St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, South Korea.
FAU - Jeong, Sikyoung
AU  - Jeong S
AD  - Department of Emergency Medicine, Daejeon St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, South Korea.
FAU - Choi, Seung Pill
AU  - Choi SP
AD  - Department of Emergency Medicine, Eunpyeong St. Mary Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, South Korea. Electronic 
      address: emvic98@catholic.ac.kr.
FAU - Woo, Seon Hee
AU  - Woo SH
AD  - Department of Emergency Medicine, Incheon St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, South Korea. Electronic 
      address: drme@catholic.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20220819
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
RN  - B5S3K2V0G8 (ChAdOx1 nCoV-19)
RN  - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
SB  - IM
MH  - 2019-nCoV Vaccine mRNA-1273
MH  - Aged
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - ChAdOx1 nCoV-19
MH  - Emergency Service, Hospital
MH  - Fever/epidemiology/etiology
MH  - Humans
MH  - Middle Aged
MH  - RNA, Messenger
MH  - Retrospective Studies
MH  - Vaccination/adverse effects
PMC - PMC9389838
OTO - NOTNLM
OT  - Adverse event
OT  - COVID-19
OT  - Emergency department
OT  - Vaccination
COIS- Declaration of competing interest The authors have no potential conflicts of 
      interest to disclose.
EDAT- 2022/08/23 06:00
MHDA- 2022/10/07 06:00
PMCR- 2022/08/19
CRDT- 2022/08/22 19:37
PHST- 2022/04/15 00:00 [received]
PHST- 2022/06/08 00:00 [revised]
PHST- 2022/08/11 00:00 [accepted]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/10/07 06:00 [medline]
PHST- 2022/08/22 19:37 [entrez]
PHST- 2022/08/19 00:00 [pmc-release]
AID - S1341-321X(22)00239-2 [pii]
AID - 10.1016/j.jiac.2022.08.013 [doi]
PST - ppublish
SO  - J Infect Chemother. 2022 Dec;28(12):1616-1622. doi: 10.1016/j.jiac.2022.08.013. 
      Epub 2022 Aug 19.